Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 24, 2026Open Access

CHI3L1 Expression in Chordoma: Implications for Immunotherapeutic Intervention

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBeatrice CampilanCGChristian GodinezJAJonathan Arditi

Discussion

Loading...

Member takes

Overview

Demonstrates CHI3L1's role as a biomarker for primary chordoma, suggesting avenues for immunotherapy.

Key Points

  • The aim is to investigate CHI3L1 expression in chordoma and its potential as an immunotherapeutic target.
  • Analyzed RNA sequencing data from the Chordoma Foundation.
  • Conducted enzyme-linked immunosorbent assays (ELISA) on commercial chordoma cell lines.
  • Evaluated CHI3L1 expression in human chordoma tumor specimens.
  • CHI3L1 expression was significantly higher in chordoma cells compared to notochordal precursors.
  • Primary chordoma tumors exhibited increased CHI3L1 expression compared to recurrent samples.
  • Findings indicate CHI3L1's potential role in tumorigenesis and as a therapeutic target.

Cite This Study

Campilan et al. (2026) studied this question.

synapsesocial.com/papers/699d3fc8de8e28729cf64756https://doi.org/10.3390/cells15040377
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract B013: Evaluating Chi3L1 as a potential target for immunotherapy in chordoma2025
  2. 2CHI3L1 as a Prognostic Biomarker and Therapeutic Target in Glioma2024 · 7 citations
  3. 3Complex immune microenvironment of chordoma: a road map for future treatment2024 · 6 citations
  4. 4CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma2025
  5. 5Characterization of Immune Cell Heterogeneity, Key B Cell Subtypes, and Macrophages Functions Using Multiplex Immunofluorescence and Single-cell RNA Sequencing in Chordomas2024